Burnett Takes Allergy Pill

Baar, Aaron; Lucas, Sloane
November 1998
Adweek Midwest Edition;11/02/98, Vol. 39 Issue 44, p2
Trade Publication
Reports that German-owned pharmaceutical company, Hoechst Marion Roussell, has moved its consumer advertising account for its Allegra allergy medication to Leo Burnett in Chicago, Illinois. Details on Burnett's assignments; Amount spent by Hoechst on consumer advertising; Features of Allegra's advertising.


Related Articles

  • Leo Burnett piles on new account wins. Wilke, Michael; Pollack, Judann // Advertising Age;11/2/1998, Vol. 69 Issue 44, p1 

    Reports that in October 1998 Leo Burnett Co. won the Hoechst Marion Roussel's $67 million Allegra allergy remedy account as well as Sara Lee Corp.'s $100 million national media buying business. How these two wins are just a part of several accounts Leo Burnett Co.'s and its subsidiaries have...

  • New drug from Hoechst.  // Chemical Business;Dec98, Vol. 12 Issue 12, p102 

    Reports that Hoechst Marion Russell (HMR) has introduced the drug Allegra in India. Relief of allergy without sedative effects; HMR as the pharmaceutical division of Hoechst AG; Impact of the drug on patients.

  • Using the Web to reach allergy sufferers. Dickinson, James G. // Medical Marketing & Media;Jul99, Vol. 34 Issue 7, p32 

    Focuses on a Web site offering information on allergy treatment launched by Hoechst Marion Roussel Inc.

  • Arava not going DTC.  // Medical Marketing & Media;Nov98, Vol. 33 Issue 11, p40 

    Reports on the decision of Hoechst Marion Roussel not to advertise its rheumatoid arthritis drug, Arava, direct-to-consumers. Plan of the company for the promotion of the drug.

  • Burnett Wins $65 Mil. Allegra Job. Barr, Aaron; Lucas, Sloane // Adweek Western Edition;11/02/98, Vol. 48 Issue 44, p54 

    Reports on Hoechst Marion Roussel Inc.'s transfer of the advertising account for its allergy medication from Medicus Communications to Leo Burnett Co. Value of the account; Burnett's responsibilities in the deal; Role of Medicus in Hoechst's move.

  • So long, Seldane. Geier, Thom // U.S. News & World Report;01/12/98, Vol. 124 Issue 1, p66 

    Reports that Hoechst Marion Roussel is discontinuing sales of Seldane, the first nonsedating allergy drug. Seldane being implicated in heart problems when used in combination with other medications; The Food and Drug Administration's recommendation that Seldane be withdrawn; Hoechst lengthening...

  • HMO enrollment, Rx spending going separate ways. Fleming Jr., Harris // Drug Topics;1/4/99, Vol. 143 Issue 1, p46 

    Features the `Managed Care Digest,' series published by Hoechst Marion Roussel on decline in drug spending. Aim of the digest; Information on the report `HMO-PPO/Medicare/Medicaid Digest released in November 1998; Budget spent by health maintenance organizations in 1997; Increase in Medicare...

  • Arava approaches approval. Petersen, Carolyn // Pharmaceutical Executive;Sep98, Vol. 18 Issue 9, THE NEWS p18 

    Focuses on the efforts of some government advisers in the United States to urge the Food and Drug administration to approve the DTC campaign of Hoechst Marion Roussel for the drug called Arava, a drug for rheumatoid arthritis. Reasons for the move of the advisers; Incidence of rheumatism in the...

  • HMR cited in Allegra `misleading' promotion. Dickinson, James G. // Medical Marketing & Media;Jun98, Vol. 33 Issue 6, p34 

    Reports that the pharmacodynamic data provided by Hoechst Marion Roussel company, on Allegra drug, has been cited as misleading by the United States Food and Drug Administration's Division of Drug Marketing Communications (DDMAC). Why the information was labeled as misleading.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics